Short- & Long-Term Impact of Subtotal Parathyroidectomy on the Achievement

Status Completed

Clinical Trial Summary

The impact of parathyroidectomy (PTX) on the bone mineral parameters in dialysis patients with secondary hyperparathyroidism (SHPT) remains unclear. The investigators performed this study to present the short- and long-term impact of PTX on calcium, phosphorus and intact parathyroid hormone control in dialysis patients with severe SHPT after operation. In particular, the investigators evaluate the impact based on the achievement of recommendations of the current clinical practice guidelines for bone and mineral parameters in dialysis patients after PTX.

Clinical Trial Description

1. A retrospective chart review of dialysis patients including referred cases, receiving surgical PTX, which was performed by one surgeon at the Far Eastern Memorial Hospital, a 1084-bed tertiary-care medical center in northern Taiwan will be performed.

2. Serum levels of calcium, phosphorus and intact parathyroid hormone were routinely measured for three consecutive post-operative days and subsequent laboratory values were checked during out-patient follow-up period. Patients with postoperative 6-month laboratory data are included in the short-term group and those with more than 6-month available data are in the long-term one.

3. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI™) Clinical Practice Guidelines provided recommended target values for serum intact parathyroid hormone (iPTH)(150-300 pg/ml), phosphorus (3.5-5.5 mg/dl), calcium (8.4-9.5 mg/dl) and the calcium-phosphorus product (<55 mg2/dl2). The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines suggested maintaining serum calcium in the reference range (8.5-10.5 mg/dl), phosphorus (2.7-4.5 mg/dl) and PTH values in the range of two to nine times the upper reference limit (130 - 585 pg/ml) in dialysis patients.

4. The investigators evaluated the impact of subtotal PTX on the control of bone and mineral parameters in dialysis patients with secondary HPT as the percentages of cases achieving the recommended K/DOQI and KDIGO targets. ;

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Hyperparathyroidism

Clinical Trial Details

NCT number	NCT01872429
Study type	Observational
Source	Far Eastern Memorial Hospital
Contact
Status	Completed
Phase	N/A
Start date	November 2012
Completion date	April 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00379899` - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4
Completed	`NCT00377312` - 7 Day Continuous Parathyroid Hormone IV Infusion	Phase 0
Completed	`NCT04040946` - Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention	Phase 3
Recruiting	`NCT03053999` - Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Withdrawn	`NCT02711059` - Insulin Resistance in Primary Hyperparathyroidism	N/A
Completed	`NCT01691781` - The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study	N/A
Completed	`NCT00538720` - Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)	Phase 1
Completed	`NCT00887666` - Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure	N/A
Terminated	`NCT03044600` - Gene Expression in Hyperparathyroidism
Completed	`NCT03747029` - Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Completed	`NCT00800358` - Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism	N/A
Recruiting	`NCT00169806` - Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis	N/A
Completed	`NCT03968510` - Swalqol in Primary Hyperparathyroidism
Completed	`NCT00501215` - Effect of Parathyroidectomy on Sleep	N/A
Completed	`NCT02591160` - Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism	N/A
Recruiting	`NCT05299632` - F-18 PSMA for Localization of Parathyroid Adenoma
Recruiting	`NCT02986607` - Corticosteroid Rhythms in Hypoparathyroid Patients	Early Phase 1
Completed	`NCT02432599` - Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas	Phase 2
Completed	`NCT02524041` - Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism	N/A
Recruiting	`NCT05667090` - Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms